Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,524	1,591	1,907	1,940	1,368	261.17
Short-Term Investments	-	-	10	-	-	-
Trading Asset Securities	-	60.26	-	100.06	360.84	-
Cash & Short-Term Investments	1,524	1,651	1,917	2,040	1,729	261.17
Cash Growth	-5.43%	-13.88%	-6.01%	18.02%	561.86%	1791.45%
Accounts Receivable	84.8	97.46	61.89	38.82	146.91	96.26
Other Receivables	1.53	4.27	2.8	1.6	8.32	10.34
Receivables	86.33	101.73	64.68	40.42	155.23	106.6
Inventory	71.82	73.4	99.32	135.2	141.7	92.39
Other Current Assets	21.33	51.57	5.37	19.6	7.2	7.82
Total Current Assets	1,703	1,878	2,087	2,235	2,033	467.99
Property, Plant & Equipment	445.94	408.81	261.58	244.68	231.02	138.65
Long-Term Investments	28.1	19.3	2.84	40	40	-
Other Intangible Assets	271.04	275.16	208.71	213.71	20.35	20.75
Long-Term Deferred Tax Assets	10.72	11.8	14.44	13.16	3.01	1.52
Long-Term Deferred Charges	-	-	0.11	0.21	0.29	4.86
Other Long-Term Assets	16.07	9.15	5.08	4.54	104.13	0.15
Total Assets	2,475	2,602	2,580	2,752	2,432	633.92
Accounts Payable	53.53	56.45	58.35	88.72	224.32	110.89
Accrued Expenses	8.77	19.08	20.02	25.94	26.32	21.33
Short-Term Debt	0.19	0.44	0.59	0.35	5.64	11.09
Current Portion of Leases	-	-	2.45	5.1	2.28	-
Current Income Taxes Payable	3.32	0.02	-	-	39	17.34
Current Unearned Revenue	14.3	7.39	47.16	44.68	18.56	8.93
Other Current Liabilities	44.59	95.23	20.85	6.28	1.44	20.99
Total Current Liabilities	124.7	178.62	149.43	171.08	317.56	190.58
Long-Term Leases	-	-	-	2.19	4.55	-
Long-Term Unearned Revenue	10.05	11.17	8.69	6.43	1.25	0.31
Long-Term Deferred Tax Liabilities	-	-	0.71	1.16	-	-
Other Long-Term Liabilities	-	-	-	8.43	-	-
Total Liabilities	134.75	189.79	158.82	189.29	323.36	190.89
Common Stock	149.33	106.67	106.67	106.67	106.67	80
Additional Paid-In Capital	756.58	790.45	813.33	814.94	814.94	12.24
Retained Earnings	1,459	1,543	1,510	1,638	1,185	351.2
Treasury Stock	-28.02	-31.61	-14.76	-	-	-
Comprehensive Income & Other	2.02	0.94	-0.36	1.21	0.7	0.7
Total Common Equity	2,339	2,409	2,415	2,561	2,107	444.14
Minority Interest	1.72	2.87	5.51	1.04	1.05	-1.11
Shareholders' Equity	2,340	2,412	2,421	2,562	2,108	443.02
Total Liabilities & Equity	2,475	2,602	2,580	2,752	2,432	633.92
Total Debt	0.19	0.44	3.04	7.64	12.47	11.09
Net Cash (Debt)	1,523	1,651	1,914	2,032	1,716	250.08
Net Cash Growth	-5.39%	-13.77%	-5.81%	18.43%	586.22%	-
Net Cash Per Share	9.70	11.20	12.83	13.60	14.15	2.23
Filing Date Shares Outstanding	149.33	148.78	146.38	149.33	149.33	112
Total Common Shares Outstanding	149.33	148.78	148.7	149.33	149.33	112
Working Capital	1,578	1,699	1,937	2,064	1,715	277.4
Book Value Per Share	15.66	16.20	16.24	17.15	14.11	3.97
Tangible Book Value	2,068	2,134	2,207	2,348	2,087	423.39
Tangible Book Value Per Share	13.84	14.35	14.84	15.72	13.97	3.78
Buildings	-	306.67	193.65	194.71	189.13	37.09
Machinery	-	96.17	90.92	81.61	66.19	37.92
Construction In Progress	-	87.23	39.65	9.85	-	88.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.